Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.

Neuro-oncology - 4 May 2022

Rudà Roberta, Bruno Francesco, Ius Tamara, Silvani Antonio, Minniti Giuseppe, Pace Andrea, Lombardi Giuseppe, Bertero Luca, Pizzolitto Stefano, Pollo Bianca, Conti Nibali Marco, Pellerino Alessia, Migliore Enrica, Skrap Miran, Bello Lorenzo, Soffietti Riccardo

Abstract excerpt

BACKGROUND: Prognostic factors and role of treatments are not well known in isocitrate dehydrogenase (IDH) wild-type (wt) grade 2 astrocytomas. The aim of this study was to define in these tumors clinical features, molecular characteristics, and prognostic factors, with particular focus on molecular subgroups defined by cIMPACT-NOW update 3. METHODS: We analyzed 120 patients with confirmed diagnosis of grade 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 34651653
DOI: 10.1093/neuonc/noab239
PMCID: PMC9071340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.PMID 34651653Read ↗

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.Semantic proximity Read ↗

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteriaSemantic proximity Read ↗

Clinical and molecular characteristics and prognostic factors of diffuse astrocytoma, IDH-wildtype, not elsewhere classified.Semantic proximity Read ↗

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.Semantic proximity Read ↗

Conventional and emerging treatments of astrocytomas and oligodendrogliomas.Semantic proximity Read ↗

IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.Semantic proximity Read ↗

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.Semantic proximity Read ↗

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.Semantic proximity Read ↗

Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas.Semantic proximity Read ↗

IDH-mutant astrocytomas with primitive neuronal component have a distinct methylation profile and a higher risk of leptomeningeal spreadSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.